Tessari L, Cavezzi A, Frullini A
Glauco Bassi Foundation, Trieste, Italy.
Dermatol Surg. 2001 Jan;27(1):58-60.
Recently a new method of using a foam sclerosing agent for the treatment of leg veins has been described. We present a pilot study of a new technique for producing the sclerosing foam (Tessari's method) (SFT) and its use in sclerotherapy of major and minor varicosities.
A preliminary multicenter experience of sclerotherapy performed by means of this new kind of sclerosing foam made of purified sodium tetradecylsulfate is described. The authors evaluated the safety and efficacy of different doses and concentrations of the drug as well as different methods of preparing the foam in addition, the results of this technique were evaluated.
Over a 6-week period the three authors performed sclerotherapy or duplex-guided sclerotherapy using SFT, treating 77 patients. The SFT was formed using a three-way stopcock and two syringes, mixing air with liquid sodium tetradecylsulfate to create a foam. Each author used different concentrations (0.1-3%) and doses (2-8 ml) of SFT according to the size and number of the veins. Alternate methods of preparing the foam were examined as well. Seventy percent of the sclerotherapy sessions were performed on either the long or short saphenous veins, recurrent varices, or collaterals. Thirty percent of the treatments were for reticular varices and telangiectases.
At 1-month follow-up, the vast majority of treated larger veins were either obliterated or showed a normal state of cephalad blood flow. Results for minor varicosities were good, but with related complications of hyperpigmentation and small areas of cutaneous necrosis. Two patients experienced transient scotomas and one patient developed segmental phlebitis of a collateral vein. The best foam was obtained by mixing one part liquid sodium tetradecylsulfate and four to five parts air, but the duration of the foam product was also related to several other factors.
This preliminary pilot study demonstrates that the technique of producing sclerosing foam according to Tessari's method (three-way stopcock device) is very promising, especially for larger veins. No serious complications were reported, and further standardization of the method may improve the results and feasibility of this technique. Further studies are needed to validate this new technique.
最近描述了一种使用泡沫硬化剂治疗腿部静脉的新方法。我们展示了一项关于制备硬化泡沫(泰萨里方法)(SFT)新技术及其在大、小静脉曲张硬化治疗中应用的初步研究。
描述了通过这种由纯化的十四烷基硫酸钠制成的新型硬化泡沫进行硬化治疗的初步多中心经验。作者评估了不同剂量和浓度的药物以及不同泡沫制备方法的安全性和有效性,此外,还评估了该技术的结果。
在6周的时间里,三位作者使用SFT进行硬化治疗或双功超声引导下的硬化治疗,治疗了77例患者。SFT通过一个三通旋塞和两个注射器形成,将空气与液体十四烷基硫酸钠混合以产生泡沫。每位作者根据静脉的大小和数量使用不同浓度(0.1 - 3%)和剂量(2 - 8毫升)的SFT。还研究了制备泡沫的替代方法。70%的硬化治疗疗程是针对大隐静脉或小隐静脉、复发性静脉曲张或侧支静脉进行的。30%的治疗是针对网状静脉曲张和毛细血管扩张。
在1个月的随访中,绝大多数接受治疗的较大静脉要么闭塞,要么显示出向头侧血流的正常状态。小静脉曲张的治疗效果良好,但伴有色素沉着和小面积皮肤坏死等相关并发症。两名患者出现短暂性暗点,一名患者发生侧支静脉节段性静脉炎。通过将一份液体十四烷基硫酸钠与四到五份空气混合可获得最佳泡沫,但泡沫产品的持续时间也与其他几个因素有关。
这项初步的试点研究表明,根据泰萨里方法(三通旋塞装置)制备硬化泡沫的技术非常有前景,特别是对于较大的静脉。未报告严重并发症,该方法的进一步标准化可能会改善该技术的结果和可行性。需要进一步的研究来验证这项新技术。